Baseline demographics and clinical characteristics (intent-to-treat population)
| Total population | ≤6 months' disease duration | >6 months' disease duration | ||||
|---|---|---|---|---|---|---|
| Characteristic | SC abatacept+MTX (n=318) | SC adalimumab+MTX (n=328) | SC abatacept+MTX (n=71) | SC adalimumab+MTX (n=70) | SC abatacept+MTX (n=247) | SC adalimumab+MTX (n=258) |
| Patients completing the study at year 2, n (%) | 252 (79.2) | 245 (74.7) | 54 (76.1) | 49 (70.0) | 198 (80.2) | 196 (76.0) |
| Median (minimum, maximum) age, years | 52 (19, 83) | 52 (19, 85) | 50 (19, 80) | 52 (22, 75) | 53 (21, 83) | 52 (19, 85) |
| Female, n (%) | 259 (81.4) | 270 (82.3) | 59 (83.1) | 51 (72.9) | 200 (81.0) | 219 (84.9) |
| White, n (%) | 257 (80.8) | 256 (78.0) | 60 (84.5) | 57 (81.4) | 197 (79.8) | 199 (77.1) |
| Geographic region, n (%) | ||||||
| North America | 230 (72.3) | 235 (71.6) | 67 (94.4) | 63 (90.0) | 163 (66.0) | 172 (66.7) |
| South America | 88 (27.7) | 93 (28.4) | 4 (5.6) | 7 (10.0) | 84 (34.0) | 86 (33.3) |
| Mean (SD) disease duration, years | 1.9 (1.4) | 1.8 (1.4) | 0.3 (0.1) | 0.3 (0.1) | 2.4 (1.3) | 2.2 (1.3) |
| Median HAQ-DI | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 |
| Median DAS28 (CRP) | 5.5 | 5.5 | 5.5 | 5.7 | 5.6 | 5.4 |
| Median CDAI | 36.2 | 36.5 | 34.4 | 38.0 | 36.2 | 39.2 |
| Median SDAI | 38.1 | 37.6 | 37.0 | 36.3 | 38.3 | 37.4 |
CDAI, Clinical Disease Activity Index; DAS28 (CRP), Disease Activity Score 28 (C-reactive protein); HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SC, subcutaneous; SDAI, Simplified Disease Activity Index.